Hydromer Inc (OTC:HYDI)

Branchburg, NJ, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hydromer, Inc. (HYDI) is partnering with EuroDev to further their presence among European based companies requiring specialty coatings for biomedical and industrial applications. With EuroDev’s vast experience in the industrial and medical markets throughout Europe and Hydromer’s 40 years of expertise in developing specialty polymer and surface modification technologies, the partnership will provide a collaborative platform to rapidly serve the needs of companies ranging from start-ups to large multinationals based in Europe. This partnership will assist in furthering Hydromer’s legendary and proven technologies into Europe and support European medical device companies that are looking to establish or expand into North American markets.

“The global hydrophilic coatings market size is vast and undergoing exceptional growth in diverse markets including, medical devices and equipment, automotive, optical, electronic and chemical. Europe is one of the largest marketplaces of overall consumption, accounting for ~ 25% of the total market. Due to rising investments in medical infrastructure and expansion, demand will continue to rise for Hydromer’s high performance specialty coatings and services in Europe. This partnership with EuroDev will help us deliver even better and faster customer service to clients based in the EU,” said Peter M. von Dyck – CEO.

Branchburg, NJ, Sept. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Board of Directors of Hydromer, Inc. (HYDI.PK – OTC BB), announces a $0.25 dividend per Common Share with a Record Date of September 24, 2018 and a Dividend Payment Date of October 8, 2018. 

Hydromer, Inc. is an innovative ISO 9001:2015 technology-focused company engaged in the business of inventing, developing, patenting, licensing, manufacturing and selling hydrophilic polymer based products for commercial markets including Medical Device, Pharmaceutical, Biotechnology, Industrial Plastics  and Cosmetic and Personal Care.   Hydromer also provides highly specialized medical coating services to industry through its FDA registered and ISO 13485:2003 certified Biosearch Medical Products subsidiary.

The Company is nearing a return to profitability. Cost management and revenue growth are the key factors and while we did not reach the same revenue levels achieved a year ago, it is certainly within reach. During the past few years, the Company’s R&D resources were dedicated to its T-HEXX Animal Health product line as that could yield the quickest revenue return (as compared with the much longer term human medical product line). Some of the recent developments in the T-HEXX product line are being rolled out into the market.

BRANCHBURG, NJ--(Marketwire - May 9, 2012) - Hydromer, Inc. (OTCQB: HYDI) (PINKSHEETS: HYDI) announced that during its last fiscal quarter, ending on March 31st, 2012, it had entered into License Agreements with three separate Chinese medical device manufacturers.

Under the terms of these agreements, each Chinese company is licensed to use certain proprietary Hydromer® medical coatings on medical devices, such as Intraocular Lens Injection nozzles, Tissue Culture Dishes and Rods, and various Intravenous Catheters.

These Chinese medical device companies will make their Hydromer coated devices available for their Chinese and International Clients.

"We are delighted with our new Chinese relationships and are proud to have our innovative Hydromer Medical Coating Technologies contribute to the growing Chinese medical device market sector", commented Martin von Dyck, Executive Vice President of Hydromer, Inc., adding, "Each of these Chinese companies is using different Hydromer Medical Coating Technologies that are formulated for their respective device material selections and coated device performance requirements."